Haleon plc
HLNCF
Other OTC4.34
USD
+0.04
- -
CIK
0001900304
ISIN
GB00BMX86B70
Return %
Stock
S&P500
1Y
-20.02
26.53
3Y
7.04
76.60
5Y
24.57
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Brian James McNamara
- Full Time Employees
- 24,561
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Building 5 Weybridge United Kingdom KT13 0NY
- IPO Date
- Jul 28, 2022
- CIK
- 0001900304
- Website
- haleon.com
- Similar Companies
- Business
- Haleon plc is a global consumer healthcare company specializing in the research, development, manufacturing, and marketing of over-the-counter (OTC) health products. Its core product portfolio includes pain relief medications, oral health products, vitamins, minerals and supplements, respiratory health products, digestive health solutions, and skin health and wellness products. Notable brands under Haleon include Sensodyne, Voltaren, Centrum, Panadol, and Gaviscon, among others. The company offers a wide range of consumer healthcare solutions encompassing analgesics; oral care; digestive health; respiratory health; and vitamins and supplements, serving diverse markets worldwide. Haleon operates internationally with significant geographic presence across North America, Europe, Latin America, Asia-Pacific, and Africa. The company was established as an independent entity in 2022 following its spin-off from GlaxoSmithKline, with headquarters located in London, United Kingdom. The company’s business segments are aligned with its strategy to be a leader in consumer healthcare by focusing on innovation, trusted brands, and broad market reach. In the last two years, Haleon has undertaken several strategic initiatives. This includes launching new product lines to address evolving consumer health needs, entering into strategic alliances to expand its digital health offerings, and making targeted acquisitions to enhance its portfolio in key therapeutic areas. Haleon’s recent activities emphasize business expansion, accelerated innovation, and strengthening its global presence to deliver sustainable growth in the consumer healthcare sector. Haleon serves varied customer types including pharmacies, retail chains, healthcare professionals, and direct-to-consumer channels. The company maintains a strong focus on over-the-counter consumer health products that support everyday wellness and manage common ailments, distinguishing itself through science-backed formulations and a portfolio of internationally recognized brands. It continues to leverage its operational scale and expertise to drive growth in established and emerging markets.